Publication

PARTNER: A randomized, phase II/III trial to evaluate the safety and efficacy of the addition of olaparib to platinum-based neoadjuvant chemotherapy in patients with triple-negative and/or germline BRCA-mutated breast cancer

Drewett, L.
; 
Lucey, R.
; 
Pinilla, K. A.
; 
Grybowicz, L.
; 
Wulff, J.
; 
Dayimu, A.
; 
Demiris, N.
; 
Vallier, A. L.
; 
Qian, W.
; 
Machin, A.
... show 10 more
Citations
Altmetric:
Abstract
Authors
Drewett, L.
Lucey, R.
Pinilla, K. A.
Grybowicz, L.
Wulff, J.
Dayimu, A.
Demiris, N.
Vallier, A. L.
Qian, W.
Machin, A.
McAdam, K.
Roylance, R.
Copson, E.
Armstrong, Anne C
Levitt, N.
Provenzano, E.
Tischkowitz, M. D.
McMurtry, E.
Earl, H. M.
Abraham, J.
Affiliation
Department of Oncology, University of Cambridge and Cambridge Breast Cancer Research Unit, Cambridge University Hospitals NHS Foundation Trust, Cambridge
Description
Date
2022
Publisher
Collections
All Christie Publications
Show all metadata
Keywords
Type
Meetings and Proceedings
Citation
Drewett L, Lucey R, Pinilla KA, Grybowicz L, Wulff J, Dayimu A, et al. PARTNER: A randomized, phase II/III trial to evaluate the safety and efficacy of the addition of olaparib to platinum-based neoadjuvant chemotherapy in patients with triple-negative and/or germline BRCA-mutated breast cancer. Journal of Clinical Oncology. 2022 Jun;40(16). PubMed PMID: WOS:000863680305051.
Journal Title
Journal ISSN
Volume Title
URI
http://hdl.handle.net/10541/625833
Embedded videos